Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal Cancer

Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab, a novel humanized anti-EGFR monoclonal antibody, and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer gastrointestinal and hematologic toxicities, according to phase 3 trial results presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting. Given these significant differences in toxicity, the trial was stopped early.
Oncology Nurse Advisor